Panagiotis Efentakis, Aimilia Varela, Sofia Lamprou, Eleni-Dimitra Papanagnou, Michail Chatzistefanou, Andriana Christodoulou, Constantinos H Davos, Maria Gavriatopoulou, Ioannis Trougakos, Meletios Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou
BACKGROUND AND PURPOSE: Cancer therapy-related cardiovascular adverse events (CAEs) in presence of comorbidities, are in the spotlight of the cardio-oncology guidelines. Carfilzomib (Cfz), indicated for relapsed/refractory multiple myeloma (MM), presents with serious CAEs. MM is often accompanied with co-existing comorbidities. However, Cfz use in MM patients with cardiometabolic syndrome (CMS) or in heart failure with reduced ejection fraction (HFrEF), is questionable. EXPERIMENTAL APPROACH: ApoE-/- and C57BL6/J male mice received 14 weeks Western Diet (WD) (CMS models)...
April 28, 2024: British Journal of Pharmacology